Executive team
)
Dr. Gordon Sanghera
Chief Executive Officer
Dr Gordon Sanghera, CBE
Dr Gordon Sanghera is the Chief Executive Officer and co-founder of Oxford Nanopore Technologies, where he has led the development of pioneering nanopore-based sensing technology since 2005. Under his leadership, the company has grown significantly, culminating in a successful listing on the London Stock Exchange in 2021. Oxford Nanopore’s platform, including the MinION, Flongle, GridION, and PromethION sequencing devices, are now used in over 125 countries, enabling real-time, high-performance analysis of DNA and RNA, with potential to expand into proteomics and metabolomics.
Before co-founding Oxford Nanopore, Dr Sanghera held key positions at MediSense, an Oxford University spin-out, where he was instrumental in launching several generations of glucose monitoring systems. His roles included, Research and Development Director, VP of Worldwide Marketing, and Manufacturing Process Development Director, where he contributed to innovations that served both consumer and hospital medical markets.
Dr Sanghera holds a PhD in bioelectronics and a BSc in chemistry, both from Cardiff University. Throughout his career, he has been recognised for his contributions to biotechnology and innovation, including being named a Commander of the Most Excellent Order of the British Empire (CBE) in 2023, for driving advancements that have had a global impact on medical and scientific research.
)
Nick Keher
Chief Financial Officer
Nick Keher
Nick Keher is the Chief Financial Officer at Oxford Nanopore Technologies, where he oversees the Group’s finance function and investor relations. He brings significant experience in financial leadership within complex scientific businesses, contributing to the company's strategic financial planning and market positioning.
Before joining Oxford Nanopore, Nick served as CFO at both Clinigen Group and Benevolent AI, both listed businesses in the pharmaceutical and biotechnology sectors. His earlier career includes a role as Managing Director and Head of the European healthcare equity research team at Royal Bank of Canada (RBC). Prior to RBC, Nick held positions at Investec and GSK, following a transition from practising pharmacy to finance.
Nick’s academic background includes qualifications in pharmacy, which laid the foundation for his deep understanding of the life sciences sector. His extensive experience in capital markets and financial management equips him with the tools to navigate the complexities of the industry, ensuring robust financial health and investor confidence for Oxford Nanopore.
)
Tim Cowper
Chief Operating Officer
Tim Cowper
Tim Cowper is the Chief Operating Officer at Oxford Nanopore Technologies, where he ensures that the company’s values of agility and entrepreneurialism are integrated into corporate governance, risk control, and business processes. Tim initially joined Oxford Nanopore as interim Finance Director in 2009, where he established a stable finance infrastructure, and later returned in 2012 as Commercial Operations Director, before being appointed COO in 2023. In his first five years with the company, Tim was instrumental in setting up and managing operations across the organisation, including leading the operations for Oxford Nanopore’s first product launch, the MinION Access Programme, in 2015. He also selected and implemented the company’s Enterprise Resource Planning (ERP) system, which has remained robust and fit for purpose throughout Oxford Nanopore’s rapid growth. Tim moved back to lead the finance team in 2017, becoming CFO in 2021 during which time he prepared the company for its listing on the London Stock Exchange.
Before joining Oxford Nanopore, Tim qualified as a Chartered Accountant at Ernst & Young and later became Financial Controller of Celltech Group plc, where he was a key member of the IPO team and managed several transactions for the listed company. Tim co-founded Sterilox, overseeing its finance function, before serving as Finance Director at Clipper Ventures plc. His career also includes roles as Finance Director at British Biotech plc (Vernalis plc) and managing a portfolio of biotech and technology companies, including the AIM-listed Bioventix plc.
Tim holds a degree in Economics from the University of Sussex.
)
Zoe McDougall
Global Head, SVP, Corporate Affairs
Zoe McDougall
Zoe McDougall is the Global Head and Senior Vice President of Corporate Affairs at Oxford Nanopore, where she leads the company's efforts to engage with a broad range of stakeholders, including scientific researchers, governments, and policymakers. Since joining the company in 2008, Zoe has shaped Oxford Nanopore’s external communications, strategic marketing, and investor relations, while also focusing on the role of culture in driving organisational effectiveness. Zoe has been central to ensuring that Oxford Nanopore’s narrative is clear and compelling to diverse audiences, helping to position the company as a leader in the genomics space.
Before joining Oxford Nanopore, Zoe gained extensive experience across the pharmaceutical and healthcare sectors. She has worked with companies such as GlaxoSmithKline and, through her role at Porter Novelli, consulted for industry leaders including Bristol-Myers Squibb, Pfizer, and Novartis, as well as emerging innovative brands.
Zoe holds a BSc in physiology from the University of Bristol and has further developed her expertise through programs at the Saïd Business School in Oxford and at the London School of Economics. Throughout her time at Oxford Nanopore, Zoe has been instrumental in building and nurturing the company’s external presence, creating communication channels that ensure the company's technology and philosophy are well understood. She played a key role in building the company's marketing functions and was an integral part of the team that led Oxford Nanopore through its IPO.
)
Jordan Herman
SVP, General Counsel
Jordan Herman
Jordan Herman is Senior Vice President and General Counsel at Oxford Nanopore Technologies, leading the company’s global legal function. Since joining Oxford Nanopore in 2021, Jordan has grown and shaped an in-house team focused on enabling business innovation, facilitating strategic growth, and ensuring robust legal and ethical compliance aligned with the company’s core values.
Jordan brings extensive expertise in technology transfer, commercial agreements, mergers and acquisitions, joint ventures, licensing, and venture capital transactions. Prior to joining Oxford Nanopore, he was a Partner at Baker Botts L.L.P., serving as Oxford Nanopore’s outside counsel for over a decade and supporting its journey from a small startup to a global leader in genomic technology. At Baker Botts, he held roles including Chair of the Austin Office Corporate Department and Co-Chair of the Life Sciences group, advising high-growth businesses across life sciences, software, medical devices, and digital media sectors worldwide.
Jordan holds a JD from The Ohio State University and a degree in Political Economy from Washington University. Following law school, he served as a judicial clerk for the Hon. James Rosenbaum, former Chief Judge for the U.S. District Court, District of Minnesota. His breadth of experience uniquely positions him to lead Oxford Nanopore’s legal strategies, navigating growth, innovation, and global compliance.
)
Jordan Herman
Chief Scientific Officer
Dr. Lakmal Jayasinghe
Dr Lakmal Jayasinghe is the Chief Scientific Officer at Oxford Nanopore Technologies, where he leads the company's scientific vision, driving groundbreaking research and development to advance innovation in nanopore sequencing and its transformative applications.
Before joining Oxford Nanopore in 2006, Dr Jayasinghe completed his PhD in chemical biology at the University of Oxford, where he was a member of the Hagan Bayley group. His research focused on the study and engineering of nanopores using genetic and chemical approaches, providing him with a deep understanding of nanopore technology. During his tenure at Oxford Nanopore, the company has achieved unprecedented advancements in sequencing accuracy, throughput, and versatility, enabling global researchers to explore applications spanning genomics, transcriptomics, and epigenetics. Lakmal has also championed advancements in direct RNA sequencing, revolutionising the study of native RNA molecules and their modifications, both in academic research and the biopharma industry. Over his time with Oxford Nanopore, Lakmal has held several leadership positions, including Senior Scientist, Principal Scientist, and Vice President, where he has led interdisciplinary R&D teams in biologics.
Dr Jayasinghe actively collaborates with worldwide academic partners to ensure that Oxford Nanopore leverages the best biological components and chemistries in its platforms. He actively supports initiatives in education, skill development, and partnerships aimed at democratising access to sequencing technology. A strong advocate for multi-omics approaches, Lakmal envisions a future where Oxford Nanopore’s technology seamlessly integrates genomics, transcriptomics, proteomics, and metabolomics to tackle complex biological questions and improve human health.
Departmental leaders
)
Stephanie Abernathy
VP, Commercial
Stephanie Abernathy
Stephanie Abernathy is Vice President, Commercial at Oxford Nanopore Technologies, where she brings extensive experience in leading high-performing commercial teams to deliver strategic growth and market expansion. Her responsibilities encompass driving commercial strategy, enhancing customer experiences, and overseeing sales initiatives that advance Oxford Nanopore’s market leadership.
Stephanie joins Oxford Nanopore following a successful tenure at Illumina, where she progressed through roles including Senior Regional Sales Director, Senior District Sales Manager, and Executive Territory Account Manager. Her leadership was recognised with multiple honours, including Illumina’s President’s Club and CEO Circle ELITE awards. Earlier roles at Eppendorf North America and Stratagene further demonstrate her proven ability to drive significant business growth and transformative customer engagement.
Stephanie holds a Bachelor of Science in Chemistry from Black Hills State University. Her deep expertise in strategic planning, team optimisation, and customer-centric growth is key to Oxford Nanopore’s ongoing commercial success.
)
Martyn Andrews
VP, Intellectual Property
Martyn Andrews
Martyn Andrews is Vice President of Intellectual Property at Oxford Nanopore Technologies, overseeing the company’s global IP strategy, portfolio management, and supporting litigation efforts. Since joining Oxford Nanopore in 2011, Martyn has been instrumental in building and protecting a comprehensive patent portfolio spanning diverse technologies including protein engineering, microfabrication, informatics, and solid-state physics. He manages a robust intellectual property estate comprising approximately 600 patents and applications globally, including key licensed IP collaborations.
With extensive experience both in-house and at a leading law firm, Martyn has spent much of his career guiding startup technology companies through complex patent landscapes and high-stakes litigation. Prior to Oxford Nanopore, he held senior IP roles at Rouse, Alere Inc., and Inverness Medical, where he led patent prosecution, supported international IP litigation, and played pivotal roles in corporate IP strategy during periods of rapid growth and major acquisitions. His industry experience is complemented by ten years as a patent examiner at the European Patent Office, specialising in electrochemistry and energy storage technologies.
Martyn holds a BSc in Chemistry and an MSc in Electrochemistry from the University of Southampton, as well as a postgraduate certificate in Intellectual Property Law from Brunel University London. He is a qualified European Patent Attorney and brings deep expertise to ensuring Oxford Nanopore’s innovations remain strategically protected worldwide.
)
Kathleen Barnes
SVP Population Health & Precision Medicine
Kathleen Barnes
Dr Kathleen Barnes is the Senior Vice President of Population Health and Precision Medicine, where she leads initiatives that integrate biomedical informatics, multi-omics platforms, and translational research to advance precision medicine and promote health equity. In her role, Dr Barnes is responsible for driving strategic projects that ensure personalised healthcare approaches are implemented effectively across diverse populations, making significant contributions to the field of genomic medicine.
Before assuming her current role, Dr Barnes had a distinguished career at leading institutions such as Johns Hopkins University and the University of Colorado. From 1993 to 2015, she was instrumental in building and leading interdisciplinary research and clinical programs at Johns Hopkins, and she later founded the Colorado Center for Personalized Medicine, further advancing the application of precision medicine. Additionally, she served as Senior Vice President of Population Genomics Health at Tempus Labs from 2021 to 2023, where she played a key role in expanding the company’s genomics initiatives.
Dr Barnes holds a BSN from the Medical College of Virginia, a PhD in biomedical anthropology from the University of Florida, and has completed a postdoctoral fellowship in immunogenetics at Johns Hopkins University. Her extensive academic and professional background positions her as a leader in population health and precision medicine, driving innovative approaches in the healthcare industry.
)
Thomas Bray
VP, Business Development
Thomas Bray
Dr Thomas Bray is Vice President, Business Development at Oxford Nanopore where he leads the company’s business development efforts. His role involves developing strategic partnerships, building channel partner networks, and supporting new clinical and research sequencing initiatives, to drive global strategic growth and support Oxford Nanopore’s partnership ecosystem.
Thomas began his career in genomics at the Edinburgh Cancer Research Centre, where he was involved in designing and testing pro-drug candidates. He then transitioned to the industry, where his fluency in Mandarin enabled him to successfully implement Oxford Nanopore’s first go-to-market strategy across Greater China. Over the past seven years, Thomas has been instrumental in driving the company’s growth in APAC, leveraging his expertise to bridge the gap between cutting-edge research and clinical implementation, until his promotion in 2025.
Thomas holds a PhD in clinical and molecular medicine from the University of Edinburgh, and an honours degree in organic chemistry from the University of Melbourne. He is passionate about advancing genomic technologies and making meaningful contributions to the field, particularly in translating innovative research into practical, clinical applications.
)
Jeremy Bryar
VP, Manufacturing
Jeremy Bryar
Jeremy Bryar is Vice President of Flow Cell and Biologics Manufacturing at Oxford Nanopore Technologies, overseeing all manufacturing operations. Since joining in 2014 as Director of Continuous Improvement, he has been pivotal in establishing the company’s first manufacturing operation and scaling it for growth. Jeremy led the design and fit-out of the MinION Building, the company’s new manufacturing and logistics site. Currently leading a team of 130, he is responsible for planning future UK expansions and developing overseas manufacturing. Jeremy is committed to advancing sequencing technology, focusing on bringing impactful products to market with broad global applications for good.
Before joining Oxford Nanopore, Jerry had a distinguished career at Abbott Laboratories, where he served in a number of senior operations roles and working as a Master Black Belt, supporting the deployment of Lean Six Sigma continuous improvement methodologies across Europe. With over 40 years of experience, he has worked extensively in the manufacture of medical devices, nutritional products, and biotechnology.
Jerry holds a strong commitment to continuous improvement and operational excellence, driving Oxford Nanopore’s manufacturing capabilities to new heights.
)
Hannah Coote
Vice President, Associate General Counsel
Hannah Coote
Hannah Coote is the Vice President, Associate General Counsel at Oxford Nanopore Technologies, where she specialises in corporate law. Since joining the company in 2020, Hannah has been a key advisor on corporate transactions, governance, compliance, and commercial matters. Her role involves collaborating with legal colleagues worldwide to establish the legal team as an innovative and pragmatic partner within the business, supporting Oxford Nanopore’s growth and strategic initiatives.
Before joining Oxford Nanopore, Hannah served as legal counsel at IP Group plc, a FTSE 250 intellectual property commercialisation company, where she provided legal services to the group and its portfolio of companies. She also held the role of company secretary for AIM-listed AI company Mirriad Advertising plc. Hannah began her legal career at the US law firm Orrick, Herrington & Sutcliffe, where she trained and qualified, specialising in venture capital and M&A transactions with a focus on the technology sector.
Hannah's extensive experience in corporate law and her dedication to supporting innovative businesses have been instrumental in her role at Oxford Nanopore, contributing to the company’s mission of driving transformative technological advancements.
)
Alvaro Correia
VP, Global Supply Chain
Alvaro Correia
Alvaro Correia is the Vice President of Global Supply Chain at Oxford Nanopore Technologies plc, responsible for leading the company’s global supply chain strategy and operations. Since joining in 2017, he has played a central role in scaling and professionalising the function, implementing advanced systems, establishing resilient processes, and building high-performing teams across sourcing, planning, warehousing, and distribution. His focus on operational agility and efficiency has supported the company’s rapid growth and enabled continuity during periods of significant global disruption.
Before joining Oxford Nanopore Technologies plc, Alvaro held senior supply chain and operations roles across the high-tech, scientific instrumentation, and manufacturing sectors. His experience includes leading international facility relocations, complex transformation programmes, and end-to-end supply chain optimisation.
He holds an MBA from Henley Business School, a HND in Mechanical Engineering from the University of Johannesburg and various supply chain qualifications from ASCM and CIPS.
)
Rhodri Davies
VP, Operations
Rhodri Davies
Rhodri Davies is the Vice President of Operations at Oxford Nanopore Technologies, where he works collaboratively across Departments to ensure alignment and delivery of the company’s strategic goals. Since joining Oxford Nanopore in 2011 as Director of Chip Production, Rhodri has led the design and delivery of scale up infrastructure projects such as MinION and Spectrum buildings and has played a crucial role the evolution of our technology and of our Technology transfer, Manufacturing and Quality functions, supporting the commercialisation of the company’s science with a customer-first focus.
Rhodri's extensive experience in microengineering, which began in 1999, has been instrumental in delivering solutions to a wide range of customers across military and commercial markets. Prior to his current role, he was the Process Manager within the Sensors & Electronics Group at QinetiQ, where he developed his expertise in material science research, product and process development, technology transfer, manufacturing, and performance management. Rhodri has contributed significantly to the field with three patents and over 12 publications.
Rhodri holds a BSc in physics from the University of Wales, and his deep technical expertise and leadership experience continue to drive the successful operation and scaling of Oxford Nanopore’s production capabilities.
)
Chris Hannan
VP, Quality Assurance and Regulatory Affairs
Chris Hannan
Chris Hannan is the Global Vice President for Quality Assurance and Regulatory Affairs at Oxford Nanopore Technologies, leading these critical functions to ensure compliance, quality, and effective market entry of the company's innovative products.
Chris brings over 30 years of extensive experience in regulatory and quality leadership across active medical devices, in vitro diagnostics, and combination products. Prior to joining Oxford Nanopore, Chris served as Chief Operating Officer at Oxehealth, managing operations, customer success, technical operations, and patient safety, and successfully brought new AI-driven software medical devices to markets in the UK, US, and Sweden.
His previous roles include COO and Vice President of Quality & Regulatory Affairs at Vision RT Ltd, overseeing global regulatory strategies, compliance, and quality assurance. Additionally, Chris held senior leadership positions at Philips Remote Diagnostic Technologies and Novartis, where he drove strategic regulatory initiatives and international compliance for complex, high-tech medical products.
)
Oliver Hartwell
VP, Strategic Planning
Oliver Hartwell
Oliver Hartwell is the Vice President of Strategic Planning at Oxford Nanopore Technologies, where he plays a key role in developing and executing long-term strategies to achieve the company’s goals and objectives. His responsibilities include analysing market trends, competitive landscapes, and internal data to inform strategic decisions, ensuring that the company’s direction aligns with its vision. Oliver works closely with the executive team and department leaders to drive strategic initiatives, optimise resource allocation, and monitor performance against strategic targets.
Oliver joined Oxford Nanopore in 2011 as an electrophysiological development scientist, where he contributed to optimising the launch product of the MinION device. Following the successful launch of the MinION through the MinION Access Programme, he transitioned to the early commercial team, leading the company’s growth in the North Europe region. After several successful roles in the commercial team, Oliver moved to the Clinical team, where he led commercial strategy for the company’s earliest diagnostic opportunities, including a drug-resistance test for TB and strategic partnerships in the HLA space.
Oliver holds an Executive MBA from Imperial College London and a BSc in biochemistry from the University of Birmingham. His extensive experience across scientific development, commercial growth, and strategic planning has been instrumental in driving Oxford Nanopore’s success.
)
Ant Jones
VP, Engineering
Ant Jones
Ant Jones is Vice President of Engineering at Oxford Nanopore Technologies, where he oversees the transformation of product concepts into fully realised, production-ready systems. His responsibilities encompass industrial design, mechanical and electronic engineering, as well as the development and validation of production processes and equipment. His work is critical to ensuring the seamless progression of Oxford Nanopore’s innovative products from idea to market.
Ant has over 20 years’ experience in product development, predominantly within the medical device sector, with a proven record of successfully guiding products from initial concept to regulatory-approved commercialisation. Before joining Oxford Nanopore, Ant served as Head of Design at Lombard Medical Technologies, where he developed a Class III AAA endovascular stent graft system, securing global regulatory approval. His extensive design experience also spans orthopaedics, in-vitro diagnostics (IVD), automotive, and plastics manufacturing.
Throughout his career, Ant has demonstrated leadership in complex engineering environments, consistently delivering innovative solutions that meet stringent regulatory standards and commercial objectives. His deep expertise ensures Oxford Nanopore continues to deliver cutting-edge, high-quality products that empower scientific discovery worldwide.
)
Sissel Juul
VP, Applications
Sissel Juul
Sissel Juul is Vice President of Applications at Oxford Nanopore Technologies, where she leads global multidisciplinary teams that demonstrate and expand the utility of Oxford Nanopore’s sequencing platforms. Her teams combine deep technical expertise with close collaborations across customers, key opinion leaders, and industry partners, developing novel applications, performing rigorous benchmarking, and converting proof-of-concept innovations into robust, end-to-end workflows and analysis tools.
Sissel joined Oxford Nanopore in 2014 and has held progressive leadership roles across genomic, emerging and commercial applications, significantly enhancing the reach and impact of nanopore sequencing in biological and clinical research. She previously co-founded the biotech start-up Zymonostics, developing diagnostics for infectious diseases. Her academic background includes postdoctoral research at Duke University and Aarhus University, focusing on innovative diagnostic technologies and personalised cancer treatment.
Sissel holds a PhD in Molecular Biology and Nanoscience from Aarhus University and was named a Duke Scholar in Molecular Medicine at Duke University School of Medicine. Her work continues to drive adoption, encourage innovation, and enable practical, impactful genomic assays worldwide.
)
Tonya McSherry
VP Commercial, EMEAI
Tonya McSherry
Tonya McSherry is the Vice President of Commercial, EMEAI at Oxford Nanopore Technologies, where she focuses on enabling the technology across Europe, the Middle East, Africa, and India. Her responsibilities ensure the success of our customers by supporting sales and support functions to deliver commercial excellence. Tonya’s leadership is key to expanding the reach and impact of Oxford Nanopore’s innovative technologies from research to clinical and applied markets. Tonya is dedicated to driving a positive change in healthcare and society which is reflected in her work at Oxford Nanopore to advance the use of genomics.
Before joining Oxford Nanopore, Tonya began her scientific career supporting the development of a newborn screening test for severe combined immunodeficiency (SCID) and later applied whole genome sequencing to study complex diseases such as diabetes and colon cancer. She has extensive experience in advancing large-scale genomic studies across the US and Europe, with roles at FibroGen, the Translational Genomics Research Institute (TGen), and Illumina. At Illumina, Tonya contributed to seeding the genome era in delivering large-scale genome sequencing through to enabling national human genome programs contributed significantly to the evolution of genomics knowledge across national health systems.
Tonya studied Biology at the University of San Diego and holds an MBA from the University of Arizona.
)
Nirmala Santiapillai
VP, Commercial Operations
Nirmala Santiapillai
Nirmala Santiapallai is Vice President of Commercial Operations at Oxford Nanopore Technologies, where she leads global customer service, technical support, and commercial operations functions. Since joining the company in 2020, Nirmala has developed regionalised customer service teams, ensuring tailored, responsive support for customers worldwide.
Nirmala brings extensive experience from the healthcare industry, spanning programme leadership, business improvement, customer experience, and commercial strategy. Before Oxford Nanopore, she held senior roles at General Electric Healthcare, focusing on marketing, commercial strategy, and customer service, enhancing operational efficiency and customer satisfaction across global teams. Her leadership has included building effective teams, driving process improvements, and successfully integrating business process outsourcing to streamline operational workflows.
Nirmala holds a PhD in Neurochemistry from the University of Cambridge and a BSc in Biochemistry from Imperial College London. She remains dedicated to continuous improvement and customer-focused innovation, emphasising automation and technical excellence to enhance customer experience and enable Oxford Nanopore’s growth ambitions.
)
David Stoddart
VP, Sample Technology
David Stoddart
David Stoddart is Vice President of Sample Technology at Oxford Nanopore Technologies, leading the development of sample and library preparation methods, kits, and comprehensive end-to-end workflows. His work is fundamental to enabling Oxford Nanopore’s vision of sequencing anything, by anyone, anywhere.
Since joining Oxford Nanopore in 2011, David has advanced through numerous roles—from Applications Scientist to Research Manager and subsequently to Director and Senior Director of Sample Technology—before his appointment as VP in 2023. His extensive expertise has been pivotal in the design and optimisation of integrated sequencing workflows that empower both research scientists and applied-market users globally.
David earned a first-class Masters in Biochemistry (MBiochem) from the University of Oxford in 2007. His connection to nanopore technology began with a DPhil at Oxford under Professor Hagan Bayley, completed in 2011, which laid the foundation for his career-long commitment to innovation in sample preparation and sequencing methodologies. David’s continued cross-functional leadership ensures the delivery of robust and accessible sequencing solutions at the forefront of genomic technology.
)
Kristen Stoops
VP, Licensing and Research Sponsorship
Kristen Stoops
Kristen Sloops is Vice President of Strategic Marketing and Business Development at Oxford Nanopore Technologies, bringing two decades of experience at the intersection of biology and informatics. She is responsible for shaping strategic marketing initiatives and fostering new business opportunities, reinforcing the company’s position as a leader in innovative genomic technologies.
Kristen has a strong track record in commercial strategy and business development within life sciences and informatics. Prior to joining Oxford Nanopore, she directed the life sciences commercial partner programme at Spotfire (now part of Tibco). Her career has included roles such as Director of Informatics Business Development at Helicos BioSciences and Senior Director of Strategic Marketing and New Business Development at Merck’s Rosetta Biosoftware business unit. In 2009, Kristen co-founded Neotron, a technology firm specialising in nuclear detection innovations.
Kristen holds both an MA and a BA in Physics. Her expertise bridges scientific research and commercial innovation, underpinning her commitment to advancing Oxford Nanopore’s strategic growth and impact across global markets.
)
Jayne Wallace
VP, Nanopore Research and Protein Sequencing
Jayne Wallace
Jayne Wallace is Vice President of Nanopore Research and Protein Sequencing at Oxford Nanopore Technologies, where she leads multidisciplinary teams of experimental and computational scientists. Her work focuses on advancing nanopore technology for protein sensing and sequencing, as well as discovering and engineering novel nanopores to enhance DNA, RNA, and protein sequencing performance.
Jayne brings extensive experience from both industry and academia, previously holding a postdoctoral research role at the University of Oxford, specialising in biomolecular simulation. She maintains strong links with the wider biophysics community, including serving on the management committee of the British Biophysical Society. Her leadership bridges the gap between theoretical insights and practical applications, significantly advancing Oxford Nanopore’s capabilities in multi-omics research.
In recognition of her contributions, Jayne received the Suffrage Science award in Engineering and Physical Sciences from the University of Oxford in 2025. She holds a PhD in Computational Biology and a degree in Physics, both from the University of Leeds. Jayne remains deeply committed to fostering innovation and mentoring the next generation of scientists within the biophysical and nanopore research communities.
)
Phil Watkins
VP, Finance
Phil Watkins
Phil Watkins is the Vice President of Finance at Oxford Nanopore Technologies, where he leads the company’s finance function. Since joining the company full-time in 2020, after consulting for Oxford Nanopore since 2018, Phil has overseen the finance department, including financial and management reporting. His role is crucial in ensuring the preparation of accurate and timely financial information, enabling senior leadership to make informed management decisions. Phil played a key role in the company’s fundraising efforts in 2019 and 2020, and has successfully led a major restructuring of the finance team.
Before his tenure at Oxford Nanopore, Phil amassed significant corporate finance experience across acquisitions, disposals, and joint ventures, and gained broad commercial experience in both the private and public sectors. He served as Managing and Finance Director of GEO Group Inc’s UK subsidiary, where he successfully secured several high-profile outsourcing contracts. Additionally, Phil held senior group finance roles at Jarvis plc, including M&A Director, and served as Finance Director for several start-up environmental tech companies.
Phil began his career at Ernst & Young and holds a BSc in agriculture from the University of Reading. His extensive experience in finance and strategic leadership has been instrumental in supporting Oxford Nanopore’s financial growth and stability.
)
Gretchen Weightman
VP & GM, APAC
Gretchen Weightman
Gretchen Weightman is the Vice President and General Manager, Asia Pacific, at Oxford Nanopore Technologies, where she leads the company's commercial strategy and business growth across one of the world's most dynamic and diverse regions—including China, Japan, South Korea, Australia, and Singapore. Her role focuses on maximising Oxford Nanopore’s impact by expanding access to innovative genomic technologies throughout the region.
Gretchen brings over 25 years of leadership experience across genomics, diagnostics, and healthcare, with an extensive background working alongside researchers, clinicians, industry innovators, governments, and patient advocates. Before joining Oxford Nanopore, she held senior positions at Illumina, significantly expanding genomic technology access across Asia, the Middle East, and Africa. Her experience includes successfully scaling businesses in complex, multinational environments, emphasising sustainability and equity in healthcare innovation.
Passionate about the transformative power of genomics, Gretchen champions Oxford Nanopore's real-time sequencing capabilities to advance multi-omics research and accelerate clinical outcomes. She is driven by the potential of nanopore technology to improve population health, enable earlier disease detection, strengthen biosecurity, and promote climate resilience. Gretchen is committed to authentic, values-driven leadership and, as a dedicated mother of two daughters, strives to model how passion, purpose, and impactful leadership can successfully align.
